Teva Pharmaceutical Industries Limited (NYSE:TEVA) Shares Bought by American Century Companies Inc.

American Century Companies Inc. increased its stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 9.9% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 216,523 shares of the company's stock after purchasing an additional 19,442 shares during the quarter. American Century Companies Inc.'s holdings in Teva Pharmaceutical Industries were worth $4,772,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Diversify Advisory Services LLC raised its stake in Teva Pharmaceutical Industries by 2.5% in the fourth quarter. Diversify Advisory Services LLC now owns 20,355 shares of the company's stock valued at $426,000 after buying an additional 496 shares in the last quarter. Sanctuary Advisors LLC lifted its stake in Teva Pharmaceutical Industries by 1.9% during the third quarter. Sanctuary Advisors LLC now owns 35,129 shares of the company's stock worth $601,000 after purchasing an additional 664 shares during the last quarter. Thrivent Financial for Lutherans boosted its holdings in Teva Pharmaceutical Industries by 0.3% in the fourth quarter. Thrivent Financial for Lutherans now owns 225,210 shares of the company's stock valued at $4,964,000 after purchasing an additional 699 shares in the last quarter. Metis Global Partners LLC boosted its holdings in Teva Pharmaceutical Industries by 6.7% in the fourth quarter. Metis Global Partners LLC now owns 13,697 shares of the company's stock valued at $302,000 after purchasing an additional 860 shares in the last quarter. Finally, DGS Capital Management LLC increased its stake in Teva Pharmaceutical Industries by 6.8% in the third quarter. DGS Capital Management LLC now owns 13,627 shares of the company's stock valued at $246,000 after purchasing an additional 872 shares during the last quarter. Hedge funds and other institutional investors own 54.05% of the company's stock.

Remove Ads

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on TEVA. UBS Group lowered their target price on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating for the company in a report on Thursday, January 30th. Barclays dropped their price objective on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating on the stock in a report on Thursday, January 30th. StockNews.com raised Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a report on Friday. Bank of America decreased their target price on Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating for the company in a research report on Thursday, March 6th. Finally, Piper Sandler boosted their price objective on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an "overweight" rating in a research note on Friday, January 17th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, Teva Pharmaceutical Industries currently has an average rating of "Moderate Buy" and a consensus price target of $23.43.

Teva Pharmaceutical Industries Stock Performance

Shares of TEVA stock traded up $0.11 during midday trading on Monday, hitting $13.91. The company had a trading volume of 17,801,043 shares, compared to its average volume of 9,775,466. The stock has a market cap of $15.77 billion, a price-to-earnings ratio of -9.59, a PEG ratio of 1.44 and a beta of 0.72. The company has a debt-to-equity ratio of 2.97, a current ratio of 0.98 and a quick ratio of 0.75. The company's 50 day simple moving average is $16.52 and its 200 day simple moving average is $18.01. Teva Pharmaceutical Industries Limited has a 52-week low of $12.51 and a 52-week high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last announced its quarterly earnings data on Wednesday, January 29th. The company reported $0.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. Research analysts anticipate that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current fiscal year.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.